<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00118287</url>
  </required_header>
  <id_info>
    <org_study_id>1926.00</org_study_id>
    <secondary_id>NCI-2011-01818</secondary_id>
    <nct_id>NCT00118287</nct_id>
  </id_info>
  <brief_title>Azacitidine and Etanercept in Treating Patients With Myelodysplastic Syndromes</brief_title>
  <official_title>Therapy of Myelodysplastic Syndrome (MDS) With Azacitidine Given in Combination With Etanercept: A Phase I/II Study.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fred Hutchinson Cancer Research Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Fred Hutchinson Cancer Research Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase I/II trial studies how well giving azacitidine together with etanercept works in
      treating patients with myelodysplastic syndromes (MDS). Drugs used in chemotherapy, such as
      azacitidine, works in different ways to stop the growth of cancer cells, either by killing
      the cells or by stopping them from dividing. Chemoprotective drugs, such as etanercept, may
      protect normal cells from the side effects of chemotherapy
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:

      I. Determine the frequency of hematologic responses in patients with MDS to 5-aza
      (azacitidine) plus etanercept.

      II. Determine the efficacy of 5-aza combined with etanercept in patients with low or
      intermediate (int)-1 risk who fail to respond to anti-thymocyte globulin (ATG) plus
      etanercept and for the purpose of this trial are considered as having progressive or &quot;more
      advanced&quot; disease.

      III. Correlate results of ex vivo/in vitro studies on phenotypic, cytogenetic and functional
      disease characteristics with in vivo treatment responses, to identify parameters that are
      associated with a high probability of response.

      OUTLINE:

      Patients receive etanercept subcutaneously (SC) twice weekly during weeks 1 and 2 and
      azacitidine SC or intravenously (IV) over 10-40 minutes on days 1-7. Treatment repeats every
      28 days for at least 3 courses. Treatment continues in the absence of disease progression or
      unacceptable toxicity.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2005</start_date>
  <primary_completion_date type="Actual">October 2008</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Frequency of Hematologic Responses, as Defined by International Working Group (IWG) Criteria</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Count of participants with a hematologic improvement (erythroid, platelet, or neutrophil response), assessed at 3 months.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">32</enrollment>
  <condition>de Novo Myelodysplastic Syndromes</condition>
  <condition>Previously Treated Myelodysplastic Syndromes</condition>
  <condition>Secondary Myelodysplastic Syndromes</condition>
  <arm_group>
    <arm_group_label>Treatment (chemotherapy, chemoprotection)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive etanercept SC twice weekly during weeks 1 and 2 and azacitidine SC or IV over 10-40 minutes on days 1-7. Treatment repeats every 28 days for at least 3 courses. Treatment continues in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>azacitidine</intervention_name>
    <description>Given SC or IV</description>
    <arm_group_label>Treatment (chemotherapy, chemoprotection)</arm_group_label>
    <other_name>5-AC</other_name>
    <other_name>5-azacytidine</other_name>
    <other_name>azacytidine</other_name>
    <other_name>Vidaza</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>etanercept</intervention_name>
    <description>Given SC</description>
    <arm_group_label>Treatment (chemotherapy, chemoprotection)</arm_group_label>
    <other_name>Enbrel</other_name>
    <other_name>ETN</other_name>
    <other_name>TNFR:Fc</other_name>
    <other_name>Tumor Necrosis Factor Receptor IgG Chimera</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Int-2 or high risk MDS patients

          -  Patients with low-risk or int-1 risk MDS by International Prognostic Scoring System
             (IPSS) criteria with:

               -  Single or multilineage cytopenia (absolute neutrophil count [ANC] &lt; 1500/μL,
                  hemoglobin [Hgb],10g/dL, or platelet count &lt; 100,000/μL); or

               -  Transfusion requirement of at least 2 units of packed red blood cells over an 8
                  week period

          -  Serum creatinine =&lt; 1.5x ULN (upper limit of normal)

          -  Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =&lt; 2x ULN

          -  Performance status =&lt; 2 (Eastern Cooperative Oncology Group [ECOG] scale, 0-5)

        Exclusion Criteria:

          -  Patients who have previously received hematopoietic stem cell transplants,
             specifically for MDS

          -  Patients with a diagnosis of acute myeloid leukemia (AML) by World Health Organization
             (WHO) criteria (i.e &gt;= 20% blasts) at time of enrollment

          -  Women of child bearing potential who are currently pregnant, lactating or who are not
             willing to use contraception during the entire duration of the study

          -  Men who are unwilling to use contraception while receiving 5-aza

          -  Patients with severe disease other than MDS which is expected to prevent compliance
             with the present protocol

          -  Patients with severe infections (pneumonia, septicemia, etc) within the 2 weeks prior
             to the anticipated start of protocol treatment

          -  Patients who are currently receiving or within the preceding 2 weeks have received
             cytotoxic therapy, hemopoietic growth factors, immunomodulatory therapy, or other
             experimental therapy for the treatment of MDS

          -  Current evidence of uncontrolled cardiac arrhythmia or congestive heart failure

          -  Platelet count =&lt; 10,000/mcl

          -  Absolute neutrophil count =&lt; 250/mcl

          -  Prior treatment with 5-aza

          -  Known or suspected hypersensitivity to azacitidine or mannitol
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bart Scott</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 8, 2005</study_first_submitted>
  <study_first_submitted_qc>July 8, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 11, 2005</study_first_posted>
  <results_first_submitted>April 17, 2017</results_first_submitted>
  <results_first_submitted_qc>April 17, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">May 24, 2017</results_first_posted>
  <last_update_submitted>April 17, 2017</last_update_submitted>
  <last_update_submitted_qc>April 17, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 24, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Fred Hutchinson Cancer Research Center</investigator_affiliation>
    <investigator_full_name>Bart Scott</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Azacitidine</mesh_term>
    <mesh_term>Etanercept</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Treatment (Chemotherapy, Chemoprotection)</title>
          <description>Patients receive etanercept SC twice weekly during weeks 1 and 2 and azacitidine SC or IV over 10-40 minutes on days 1-7. Treatment repeats every 28 days for at least 3 courses. Treatment continues in the absence of disease progression or unacceptable toxicity.
azacitidine: Given SC or IV
etanercept: Given SC</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="32"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Intracranial haemorrhage</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Muscle pain</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Treatment (Chemotherapy, Chemoprotection)</title>
          <description>Patients receive etanercept SC twice weekly during weeks 1 and 2 and azacitidine SC or IV over 10-40 minutes on days 1-7. Treatment repeats every 28 days for at least 3 courses. Treatment continues in the absence of disease progression or unacceptable toxicity.
azacitidine: Given SC or IV
etanercept: Given SC</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="32"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="69" lower_limit="31" upper_limit="86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="31"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Frequency of Hematologic Responses, as Defined by International Working Group (IWG) Criteria</title>
        <description>Count of participants with a hematologic improvement (erythroid, platelet, or neutrophil response), assessed at 3 months.</description>
        <time_frame>Up to 2 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment (Chemotherapy, Chemoprotection)</title>
            <description>Patients receive etanercept SC twice weekly during weeks 1 and 2 and azacitidine SC or IV over 10-40 minutes on days 1-7. Treatment repeats every 28 days for at least 3 courses. Treatment continues in the absence of disease progression or unacceptable toxicity.
azacitidine: Given SC or IV
etanercept: Given SC</description>
          </group>
        </group_list>
        <measure>
          <title>Frequency of Hematologic Responses, as Defined by International Working Group (IWG) Criteria</title>
          <description>Count of participants with a hematologic improvement (erythroid, platelet, or neutrophil response), assessed at 3 months.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Erythroid response</title>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Platelet response</title>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Neutrophil response</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No response</title>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Withdrawn from study</title>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Treatment (Chemotherapy, Chemoprotection)</title>
          <description>Patients receive etanercept SC twice weekly during weeks 1 and 2 and azacitidine SC or IV over 10-40 minutes on days 1-7. Treatment repeats every 28 days for at least 3 courses. Treatment continues in the absence of disease progression or unacceptable toxicity.
azacitidine: Given SC or IV
etanercept: Given SC</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Splenic rupture with splenectomy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiopulmonary arrest resulting in death</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Gall Bladder removal with benign mass</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Endocarditis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>CNS hemorrhages</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Hemoptysis and fever</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Pulmonary nodule</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Coagulopathy</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Lymphopenia</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Transfusion reaction</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Petechia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial fibrillation/flutter</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Congestive heart failure</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Elevated cardiac enzymes</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Ileus</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Rectal or GI bleeding</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Nausea/Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Mouth/Gum Bleeding</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Weakness</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Gallstones</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Hematuria</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Hyperbilirubinemia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration, 1 with diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Hyperglycemia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Hyperglycemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Hyponatremia</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthritis, Joint pain</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Compression fractures</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Gout</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Limited upper extremity function, after injury</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Dyspnea on exertion</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Pleural effusions</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Hemoptysis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Bleeding from cuts</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Hives, urticaria</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Squamos cell carcinoma removal</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hematoma</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Bart Scott</name_or_title>
      <organization>Fred Hutchinson Cancer Research Center</organization>
      <phone>206-667-1990</phone>
      <email>bscott@fredhutch.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

